In ₹ Crore except Per Share 12 Months Ending | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Last 12M 30/06/2026 | |
|---|---|---|---|---|---|
| Adjustments to Reconcile Profit — Non-cash Items | |||||
| + Depreciation & Amortisation | 5.2 | 5.0 | 5.7 | — | |
| + Impairment Loss / (Reversal) | -0.3 | 0.1 | 0.3 | — | |
| + Finance Costs | 3.4 | 4.1 | 6.8 | — | |
| + Interest Income | -3.0 | -2.6 | -1.4 | — | |
| + Fair Value (Gains) / Losses | -0.2 | -0.4 | -0.0 | — | |
| + Unrealised FX (Gain) / Loss | -0.4 | 0.2 | 0.6 | — | |
| + Other Non-cash Items | -2.2 | -0.8 | -0.2 | — | |
| + Other — Cash Effects are Investing / Financing | -1.9 | -1.2 | -7.2 | — | |
| Changes in Working Capital | |||||
| + Inventories | -2.9 | -49.5 | -28.1 | — | |
| + Trade Receivables — Current | -2.0 | -8.8 | -16.4 | — | |
| + Other Financial Assets — Current | 1.2 | 1.1 | -3.1 | — | |
| + Other Financial Assets — Non-current | 2.8 | -0.9 | -0.7 | — | |
| + Other Current Assets | -0.3 | -1.6 | -1.1 | — | |
| + Other Non-current Assets | 0.0 | -0.1 | 0.2 | — | |
| + Trade Payables — Current | -1.6 | 3.6 | 3.4 | — | |
| + Other Financial Liabilities — Current | -1.6 | 1.3 | 1.0 | — | |
| + Other Current Liabilities | -1.2 | -1.5 | 2.9 | — | |
| + Provisions — Current | -0.0 | 0.8 | 0.2 | — | |
| + Provisions — Non-current | 0.2 | 0.1 | 0.2 | — | |
| Cash from Operating Activities | |||||
| Profit Before Tax (per I/S) | 9.6 | 16.1 | 15.2 | 18.6 | |
| + Total Adjustments (incl. Working Capital) | -5.0 | -51.1 | -37.0 | — | |
| Cash from Operations (pre-tax) | 4.5 | -35.0 | -21.8 | — | |
| + Income Taxes Paid | 0.1 | 0.3 | 0.1 | — | |
| Cash from Operating Activities | 4.5 | -35.3 | -21.8 | — | |
| Cash from Investing Activities | |||||
| + Acq of Fixed Assets (Capex) | 12.1 | 7.3 | 8.9 | — | |
| + Acq of Intangible Assets | 0.0 | 0.0 | 0.0 | — | |
| + Disp of Fixed Assets | 2.6 | 2.3 | 9.7 | — | |
| + Acq of Intangibles under Development | 0.2 | 0.0 | 0.0 | — | |
| + Acq of Investment Property | 0.0 | 0.1 | 0.0 | — | |
| + Acq of Biological Assets | 0.0 | 0.0 | 0.0 | — | |
| + Disp of Biological Assets | 0.0 | 0.0 | 0.8 | — | |
| + Disp of Other Long-term Assets | 0.0 | 0.0 | 17.5 | — | |
| + Interest Received — Investing | 1.7 | 2.0 | 1.2 | — | |
| + Other Inflows / (Outflows) — Investing | 1.0 | -19.7 | 0.0 | — | |
| Cash from Investing Activities | -7.0 | -22.9 | 20.2 | — | |
| Cash from Financing Activities | |||||
| + Proceeds from Borrowings | 7.0 | 46.4 | 8.8 | — | |
| + Repayment of Borrowings | 0.2 | 0.5 | 0.0 | — | |
| + Payment of Lease Liabilities | 0.2 | 0.5 | 0.4 | — | |
| + Interest Paid | 3.1 | 3.7 | 6.4 | — | |
| + Dividends Paid | 4.7 | 4.7 | 5.1 | — | |
| + Other Inflows / (Outflows) — Financing | -0.1 | -0.0 | 0.0 | — | |
| Cash from Financing Activities | -1.3 | 37.0 | -3.1 | — | |
| Net Changes in Cash (pre-FX) | -3.8 | -21.2 | -4.7 | — | |
| + Effect of FX Rate Changes on Cash | 0.0 | 0.1 | 0.1 | — | |
| Net Changes in Cash | -3.8 | -21.1 | -4.6 | — | |
| Closing Cash | 35.1 | — | — | — | |
| Reference Items | |||||
| EBITDA | 9.1 | 18.9 | 17.6 | 20.5 | |
| EBITDA Margin % | 3.08 | 5.62 | 4.22 | 4.65 | |
| Free Cash Flow (CFO − Capex) | -7.7 | -42.6 | -30.8 | -30.8 | |
| Free Cash Flow to Equity | — | -0.4 | -28.4 | — | |
| Free Cash Flow per Basic Share | -9.83 | -54.45 | -39.32 | -39.32 | |
| Cash Flow to Net Income | 0.42 | -2.43 | -1.66 | — | |
| Cash Paid for Taxes | 0.1 | 0.3 | 0.1 | — | |
| Cash Paid for Interest | 3.1 | 3.7 | 6.4 | — | |